证券代码：301126 证券简称：达嘉维康 公告编号：2025-079 二、对外担保进展情况 近日，公司与中国银行股份有限公司固原支行（以下简称"中国银行"）签 订了《最高额保证合同》，同意为控股子公司宁夏德立信医药有限责任公司（以 下简称"宁夏德立信"）提供总额度人民币 1,000 万元的保证担保；公司与兴业银 行股份有限公司长沙分行（以下简称"兴业银行"）签订了《最高额保证合同》， 同意为全资子公司达嘉维康生物制药有限公司（以下简称"达嘉生物"）提供总 额度人民币 1,000 万元的保证担保，同意为全资子公司湖南达嘉维康医药营销有限 公司（以下简称"达嘉营销"）提供总额度人民币 1,000 万元的保证担保。 三、被担保人的基本情况 （一）被担保人：宁夏德立信医药有限责任公司 1 湖南达嘉维康医药产业股份有限公司 关于对外担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）为满足公司全资 子公司及控股子公司日常生产经营和业务发展资金需要，保证公司业务顺利开展， 公司于 2025 ...

Group 1 - The core viewpoint of the news is that Dajia Weikang's stock performance and financial metrics indicate a mixed outlook, with a decline in net profit despite a slight increase in revenue [1][2]. - On December 24, Dajia Weikang's stock price fell by 0.85%, with a trading volume of 121 million yuan. The financing buy-in amount was 10.85 million yuan, while the financing repayment was 13.39 million yuan, resulting in a net financing outflow of 2.55 million yuan [1]. - As of December 24, the total margin balance for Dajia Weikang was 75.37 million yuan, with the financing balance accounting for 2.85% of the circulating market value, indicating a high level compared to the past year [1]. Group 2 - As of December 10, the number of shareholders for Dajia Weikang was 16,000, a decrease of 2.42% from the previous period, while the average circulating shares per person increased by 2.48% to 8,620 shares [2]. - For the period from January to September 2025, Dajia Weikang reported operating revenue of 4.13 billion yuan, a year-on-year increase of 3.69%, but the net profit attributable to shareholders decreased by 86.02% to 5.10 million yuan [2]. - Dajia Weikang has distributed a total of 42.59 million yuan in dividends since its A-share listing, with 35.57 million yuan distributed over the past three years [3].

Group 1 - The core viewpoint of the news is that Dajia Weikang's stock performance and financial metrics indicate a mixed outlook, with a decline in net profit despite a slight increase in revenue [2][3] - On December 23, Dajia Weikang's stock fell by 1.30%, with a trading volume of 161 million yuan. The financing buy-in amount was 17.99 million yuan, while the net financing buy-in was 7.12 million yuan [1] - As of December 23, the total balance of margin trading for Dajia Weikang was 77.92 million yuan, with the financing balance accounting for 2.92% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of December 10, the number of shareholders for Dajia Weikang was 16,000, a decrease of 2.42%, while the average circulating shares per person increased by 2.48% to 8,620 shares [2] - For the period from January to September 2025, Dajia Weikang achieved an operating income of 4.13 billion yuan, a year-on-year increase of 3.69%, but the net profit attributable to shareholders decreased by 86.02% to 5.10 million yuan [2] - Dajia Weikang has distributed a total of 42.59 million yuan in dividends since its A-share listing, with 35.57 million yuan distributed over the past three years [3]

Core Viewpoint - The establishment of the Regenerative Medicine Clinical Research Center at Hunan University aims to integrate industry, academia, and research to drive innovation in the field of regenerative medicine, focusing on major disease diagnosis and treatment, as well as organ damage repair [1][2]. Group 1: Center Establishment and Objectives - The center is a collaboration involving Hunan University, Hunan Provincial Tumor Hospital, and several other medical institutions, designed to promote a new path for the integration of research and industry [1]. - The center will leverage clinical needs to guide research and innovation, aiming to create a closed loop from basic research to clinical application and industrial transformation [2]. Group 2: Industry Context and Market Potential - The global cell therapy market has surpassed $400 billion, indicating significant growth potential in the regenerative medicine sector [2]. - Hunan Province is working to develop a trillion-level stem cell and regenerative medicine industry chain, with a focus on innovation and collaboration among various stakeholders [2]. Group 3: Strategic Contributions and Infrastructure - Dajia Weikang, as a co-builder of the center, will invest in technology, talent, and funding to accelerate the transition of cutting-edge therapies from the lab to clinical practice [1]. - The center will establish a cell seed bank and regenerative medicine product library, aiming to create an internationally competitive application testing center for stem cells and regenerative medicine products [2].

Group 1 - The implementation of the "Regulations on the Management of Clinical Research and Clinical Translation Applications of New Biomedical Technologies" has brought "cell therapy" and "cell drugs" into public life, shaping the future of the life and health industry [1] - The establishment of the Regenerative Medicine Clinical Research Center at Hunan University aims to integrate advantages from industry, academia, research, and medicine, focusing on major disease diagnosis and treatment, as well as tissue and organ damage repair [1] - The center will drive research through clinical needs and empower the industry with expertise, creating a new path for the integration of research and industry, leading to high-quality development in the regenerative medicine sector [1] Group 2 - The global cell therapy market has surpassed $400 billion, and Hunan Province is working to build a trillion-yuan-level stem cell and regenerative medicine industry chain [2] - The center will focus on breakthroughs in key core technologies and establish a comprehensive stem cell traceability system, including a cell seed bank and a regenerative medicine product library [2] - The center aims to produce high-quality innovative results in talent cultivation, technology development, clinical trials, and application promotion in the field of regenerative medicine, contributing to the high-quality development of the biopharmaceutical industry [2] Group 3 - The Dajia Weikang Regenerative Medicine Research Institute is a significant strategic layout in the life and health field, committing to accelerate the transition of cutting-edge therapies from the laboratory to clinical practice [2] - Dajia Weikang has established a GMP-compliant cell bank and laboratory, creating a complete industry chain from cell collection, storage, preparation to application, enhancing the safety and effectiveness of products [2] - The goal is to ensure that the public feels confident and capable of using cell therapy products [2]

Market Overview - A-shares showed mixed performance on December 18, with the Shanghai Composite Index rising by 0.16% to 3876.37 points, while the Shenzhen Component Index fell by 1.29% to 13053.97 points, and the ChiNext Index dropped by 2.17% to 3107.06 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.66 trillion, with nearly 2900 stocks rising [1] Sector Performance Banking Sector - Bank stocks experienced a broad increase, with Shanghai Bank and Chongqing Rural Commercial Bank rising over 3% [1] Retail Sector - Retail concepts showed strength, with Central Plaza and Shanghai Jiubai hitting the daily limit [1] Commercial Aerospace - The commercial aerospace sector was active, with multiple stocks including Shengyang Technology and Shunhao Co. hitting the daily limit [1][2] Pharmaceutical Sector - The pharmaceutical sector continued to perform well, with stocks like Luyan Pharmaceutical and Zhongyao Holdings hitting the daily limit [1][3] Consumer Sector - The consumer sector, including retail, apparel, and food and beverage, led the gains, with stocks like Baida Group achieving six consecutive limits [1][4] Institutional Insights Economic Policy Outlook - Everbright Securities anticipates a favorable cross-year market for A-shares, supported by ongoing domestic economic policies and historical performance trends [5] - Huaxi Securities suggests focusing on the consumer sector as technology rotation slows down, with an emphasis on the high-low cut logic [6] - Bank of China Securities views A-shares as being in a "bull market continuation" phase, highlighting the importance of technology and anti-involution themes for future investment [7]

Market Overview - Major indices opened lower on December 18 but rebounded, with the Shanghai Composite Index turning positive by the time of reporting [1] - Sectors such as securities, coal, and oil saw significant gains, while CPO concepts, aquaculture, hotel and catering, semiconductors, and building materials faced declines [1] Healthcare Sector - The healthcare commercial concept continued to strengthen, with Huaren Health (301408) hitting a 20% limit up, and other companies like Luyuan Pharmaceutical and Zhongyao Holdings also reaching their limit up [1] AI and Financial Services - Ant Group's AI health app "Antifufu" saw a surge in downloads, ranking third on the Apple app chart, with over 15 million monthly active users and over 5 million health inquiries daily [3] - China International Capital Corporation (CICC) announced plans to merge with Dongxing Securities and Xinda Securities through a share swap, with CICC's A-shares set to be suspended from trading starting November 20, 2025, and resuming on December 18, 2025 [3] IP Economy - The IP economy concept was active, with companies like Guobo Co. and Sanxiang Impression hitting the limit up, while others like Deyi Cultural and Chuangyuan Co. also saw gains [5] - The Ministry of Commerce and other departments issued a notice to enhance collaboration between commerce and finance to boost consumption, focusing on new consumption models such as green consumption and AI + consumption [5] - The market for the "Guzi economy" is projected to reach 168.9 billion yuan in 2024, a 40.63% increase from 2023, indicating rapid growth in related sectors [5] Retail Sector Trends - Dongwu Securities highlighted that 2025 will be a significant year for retail reform, with traditional retailers improving product and service quality through adjustments [7] - The focus on enhancing product quality in the retail sector is supported by policies encouraging such improvements, particularly in less competitive lower-tier markets [7] - Kaifeng Securities noted that offline retail businesses are transitioning from selling products to offering services and experiences, leveraging their advantages to attract traffic [7]

每经AI快讯，医药板块盘初走强，华人健康涨超15%，鹭燕医药、重药控股涨停，达嘉维康、人民同 泰、漱玉平民等跟涨。 每日经济新闻 ...

（文章来源：证券日报） 证券日报网讯 12月16日，达嘉维康在互动平台回答投资者提问时表示，公司旗下子公司嘉辰医院目前 各科室运营平稳，整体经营状况良好。后续相关进展，敬请关注公司披露的相关公告。 ...

Group 1 - The core viewpoint of the article is that Dajia Weikang has confirmed the availability of mercury thermometers and medical electronic thermometers in its retail pharmacies [2] Group 2 - Dajia Weikang responded to investor inquiries on an interactive platform regarding the sales of temperature monitoring products [2]